Biocarbon device for cutaneous ureterostomy

Pow-Sang, Julio; Ojeda, J.M. Duarte; Benavente, Victor

doi:10.1016/0090-4295(84)90170-5

Cited by 5 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urinary fistula is the result of leakage from the a nas tomosis. This complication occurred in 40% of th e cases in a previous report on Biocarbon cutaneous ure te rostomy device (10). Angulation of the urete r a t the tip of the prosthesis was suggested to be the m ain ca use.…”

Section: Discussionmentioning

confidence: 92%

Clinical Experience With An Alloplastic Stoma Prosthesis (Biocarbon®) For Urinary Conduits And Cutaneous Ureterostomy

Månsson

Harzmann²

1988

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

An alloplastic stoma prosthesis, Biocarbon, composed of 99.9% pure carbon in vitreous form, was used in six patients with conduit urinary diversion and in seven with cutaneous ureterostomy. The patients were thereafter observed for 2-86 months. Complications were subcutaneous infection, urinary fistula and ureteral stenosis, which necessitated removal of the prosthesis in most cases. The permanent stoma, without need for adhesive collecting device, was appreciated by the patients. Problems relating to biocompatibility remain to be solved before the place of the stoma prosthesis in urinary diversion can be determined.

show abstract

Section: Discussionmentioning

confidence: 92%

Clinical Experience With An Alloplastic Stoma Prosthesis (Biocarbon®) For Urinary Conduits And Cutaneous Ureterostomy

Månsson

Harzmann²

1988

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…EMP also acts as a radiosensitizing agent for human prostatic cancer cells (DU-145) transplanted into nude mice [12]. EMP is therefore considered to have radiosensitizing properties [13]. In the present study, we compared the outcome of neoadjuvant luteinizing hormone-releasing hormone (LHRH) agonist plus EMP and three-dimensional conformal radiotherapy (3D-CRT) with that of neoadjuvant LHRH agonist alone and 3D-CRT in a randomized prospective trial for patients with intermediate-to high-risk prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study

et al. 2009

View full text Add to dashboard Cite

The present results indicate that the combination of neoadjuvant ADT plus EMP combined with 3D-CRT sustains freedom from PSA relapse in patients with intermediate- to high-risk prostate cancer. However, this regimen is insufficient for preventing biochemical failure, and an additional intervention such as adjuvant ADT, radiation dose escalation, or both, is required, especially for patients with a pretreatment PSA level of more than 20 ng/ml and high-grade cancer.

show abstract

Biocarbon ureterostomy device for urinary diversion Multicenter clinical trial

Chancellor¹,

Grossman²,

Κοnnak³

et al. 1989

Urology

View full text Add to dashboard Cite

The bioCarbon ureterostomy device is a stomal prosthesis for upper tract urinary diversion that has had preliminary successes in animal and human trials in Europe and Peru. Implantation of a pure carbon stomal prosthesis offers the potential advantages of high biocompatibility, lack of encrustation, and elimination of stomal stenosis which is frequently associated with cutaneous ureterostomy. Nine bioCarbon ureterostomy devices were implanted from August, 1984 through July, 1985. Although successful implantation was achieved in 2 patients, the complication rate was high. The bioCarbon ureterostomy device has potential as an alternative form of urinary diversion. However, significant problems need to be remedied before it can be recommended for routine clinical application.

show abstract

Biocarbon device for cutaneous ureterostomy

Cited by 5 publications

References 1 publication

Clinical Experience With An Alloplastic Stoma Prosthesis (Biocarbon®) For Urinary Conduits And Cutaneous Ureterostomy

Clinical Experience With An Alloplastic Stoma Prosthesis (Biocarbon®) For Urinary Conduits And Cutaneous Ureterostomy

Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study

Biocarbon ureterostomy device for urinary diversion Multicenter clinical trial

Contact Info

Product

Resources

About